StreetInsider.com News Articles

Dermata reports cosmetic study results for Tome skin treatment

Thu, 15 Oct 2026 08:06:23 -0400

Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced topline results from a cosmetic clinical study evaluating its Tome Foundational Treatment, a once-weekly skin renewal product, according to a company press release.

The open-label study included 31 participants who applied Tome Foundational Treatment once per week for four weeks. An investigator evaluated participants at multiple timepoints on endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance. Participants also completed self-evaluations after four treatments.

The company reported that 93% of participants agreed the treatment was comparable to a professional in-office procedure, and 90% agreed they saw more noticeable results compared with other

Dermata reports cosmetic study results for Tome skin treatment

Thu, 15 Oct 2026 08:06:23 -0400

The company reported that 93% of participants agreed the treatment was comparable to a professional in-office procedure, and 90% agreed they saw more noticeable results compared with other

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment

Thu, 15 Oct 2026 08:05:00 -0400

SAN DIEGO, CA / ACCESS Newswire / October 15, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Tome Foundational Treatment is now available for purchase at www.tomeskincare.com either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price.

Dermata's recently completed cosmetic clinical study consisted of 31 participants in an open label

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment

Thu, 15 Oct 2026 08:05:00 -0400

Dermata's recently completed cosmetic clinical study consisted of 31 participants in an open label

Form S-3 Dermata Therapeutics,

Fri, 09 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261009/27171578.html

Dermata launches first Tome skincare product for consumers

Tue, 25 Aug 2026 08:31:17 -0400

Dermata Therapeutics (NASDAQ: DRMA) has launched its first direct-to-consumer skincare product, the Tome Foundational Treatment, the company announced in a press release dated August 25, 2026.

The product is available for purchase at the company's website as either a one-time purchase or through a monthly subscription at a discounted price. The treatment is designed to be used once weekly and is intended to improve skin tone and texture over time.

The Foundational Treatment uses an ingredient the company calls Bioneedle, described as a purified powder derived from Spongilla lacustris, a freshwater sponge. Dermata says the ingredient is wild harvested and minimally processed.

Gerry

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Tue, 25 Aug 2026 08:30:00 -0400

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -

- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -

- Consumers can purchase a one-month kit or subscribe for convenient recurring delivery -

SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Tue, 25 Aug 2026 08:30:00 -0400

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -

- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -

- Consumers can purchase a one-month kit or subscribe for convenient recurring delivery -

Dermata opens preorders for Tome skincare product at $178

Fri, 21 Aug 2026 08:30:11 -0400

Dermata Therapeutics (NASDAQ: DRMA) announced that preorders are now open for its Tome Foundational Treatment, a once-weekly topical skin mask, with shipping expected to begin August 25, 2026.

The product retails for $178 per unit, which the company says equates to approximately $45 per treatment. Subscribers receive a 10% discount. Each purchase includes four once-weekly treatments, with each treatment containing a cup of the company's Bioneedle powder, a tube of Activator, and an application brush. Consumers mix the product before applying it as a mask.

The Tome Foundational Treatment is described by the company as its first direct-to-consumer skincare product and the

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Fri, 21 Aug 2026 08:30:00 -0400

- Preorders can be made by visiting www.tomeskincare.com -

- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -

- Tome Foundational Treatment is a once-weekly topical mask for skin renewal -

SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Fri, 21 Aug 2026 08:30:00 -0400

- Preorders can be made by visiting www.tomeskincare.com -

- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -

- Tome Foundational Treatment is a once-weekly topical mask for skin renewal -

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: PROEHL GERALD T

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945537.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: PROEHL GERALD T

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945537.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: Van Hoose Kyri K.

Tue, 18 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260818/26945502.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: Van Hoose Kyri K.

Tue, 18 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260818/26945502.html

Form 25-NSE Dermata Therapeutics, Filed by: Nasdaq Stock Market LLC

Mon, 17 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260817/26938234.html

Form 25-NSE Dermata Therapeutics, Filed by: Nasdaq Stock Market LLC

Mon, 17 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260817/26938234.html

Dermata Therapeutics raises $3.4M in private placement

Mon, 17 Aug 2026 08:31:41 -0400

Dermata Therapeutics, Inc. (NASDAQ: DRMA) has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, according to a company statement.

The offering includes 2,293,608 shares of common stock, or pre-funded warrants in lieu thereof, at a purchase price of $1.46 per share. The offering also includes series E warrants and series F warrants, each to purchase up to 2,293,608 shares of common stock, with an exercise price of $1.46 per share.

The series E warrants expire five years from the effective date of stockholder approval, while the series F warrants expire 24 months from that date. Both warrant

Form 8-K Dermata Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26935371.html

Form 8-K Dermata Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26935371.html

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mon, 17 Aug 2026 08:30:00 -0400

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants

SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mon, 17 Aug 2026 08:30:00 -0400

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants

Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 19c

Tue, 11 Aug 2026 16:56:57 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html